Open Label Continuation Study in Moderate to Severe Psoriasis

AbbVie

Status and phase: Completed; Phase 3

Conditions: Moderate to Severe Plaque Psoriasis

Treatments: Drug: ABT-874

Study type: Interventional

Funder types: Industry

Identifiers

NCT00626002

M10-016

2007-005955-40 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.

Enrollment: 2,301 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Having participated in a preceding ABT-874 clinical trial for ABT-874
• Subject has a clinical diagnosis of moderate to severe plaque psoriasis

Exclusion criteria

• Subjects who prematurely discontinued in any preceding psoriasis study with ABT-874 other than protocol-required discontinuation

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

2,301 participants in 1 patient group

1

Experimental group

Treatment:

Drug: ABT-874